Compare BHP Billiton Limited (BHP) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BHP Billiton Limited vs BIO-TECHNE Corp — how do they compare? BHP Billiton Limited trades at $84.9 (market cap $205.61B), while BIO-TECHNE Corp trades at $71.23 (market cap $11.10B). The key difference: BHP Billiton Limited is far larger — about 18.5× BIO-TECHNE Corp's market cap, and BHP Billiton Limited pays the higher dividend (3.15%). Which is the better fit depends on your goals.
| BHP | TECH | |
|---|---|---|
Market Cap | $205.61B | $11.10B |
Sector | Basic Materials | Health |
52-Week High | $93.15 | $71.38 |
52-Week Low | $50.37 | $43.31 |
Enterprise Value | $219.82B | $11.18B |
Dividend Yield | 3.15% | 0.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BHP trades at $81.37, down 0.38% with neutral technical signals. The stock shows strong profitability with 18.97% net margin and 20.13% ROE, though recent earnings missed expectations in Q4 2025. Cash flow remains positive with $75M net in 2024, while debt-to-asset ratio increased to 17.65%. Recent news highlights labor strikes and a $2.3B writedown at the Jansen potash project.
Outlook is mixed: solid fundamentals and analyst buy ratings (22.58%) support potential upside, but near-term risks from operational disruptions and cost overruns may pressure shares. Investors should weigh strong cash generation against execution challenges under new leadership.
Bio-Techne (TECH) trades at $71.36, showing minimal daily movement (+0.08%) as the market digests Merck KGaA's $73 per share acquisition offer. The stock sits just 2.3% below the buyout price, with technical indicators showing bullish momentum. Fundamentally, the company maintains strong gross margins (64.96%) but faces declining net income margins (6.01% in 2025). Recent earnings show mixed results with one beat and two misses in the last four quarters.
The acquisition premium provides near-term upside potential, though shareholder litigation risks exist regarding deal fairness. Long-term investors face uncertainty about post-acquisition prospects, while current valuation metrics (P/E 101.94) appear stretched without the takeover scenario. The $73 offer price represents the primary catalyst, with downside risk to $50 if the deal fails.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BHP Billiton Limited
BHP Group Limited operates as a mining company. The Company engages in the exploration, development, production, and processing of iron ore, metallurgical coal, and copper. BHP Group serves customers worldwide.
Read more on BHP →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
